Construction is well underway of a new multi-million pound production plant at pharmaceutical manufacturer GSK’s Montrose facility.
Following public consultation and planning approval in 2014, construction of the new Active Pharmaceutical Ingredient (API) facility has been ongoing for a number of months. Over the last week, the steel skeleton of the building has emerged.
The new facility, to be operational by mid-2016, will produce active ingredients for GSK’s next generation of respiratory medicines such as Relvar, Anoro and Incruse.
It is estimated that it will contribute up to £1 million per year to the local economy.
GSK Montrose employs nearly 400 people. The expansion will create around 25 new jobs in production, engineering and technical.
Recruitment is expected to start towards the end of 2015.
The Montrose site has been an important part of GSK’s respiratory medicine supply chain for over 40 years.
The plant started producing salbutamol sulphate, the active ingredient in Ventolin, in 1970, and still does.
The site has produced ingredients for a number of GSK’s asthma and Chronic Obstructive Pulmonary Disease (COPD) medicines such as Becotide, Serevent and Seretide.
Every day, over 20 million people worldwide take medicine manufactured at Montrose.
GSK said: “This is a very important development for the Montrose site. GSK is the world leader in respiratory medicine and here at Montrose we have been a cornerstone of that therapeutic area for over 40 years.
“The expansion enhances Montrose’s position in GSK’s network, secures a number of new jobs and is a significant boost to the local economy.”